NCT06562348 (ctDNA-RECIST) is a Phase 2 clinical trial of Standard of care in Gastrointestinal Neoplasm, sponsored by Karen-Lise Garm Spindler.

Who is sponsoring NCT06562348?

NCT06562348 is sponsored by Karen-Lise Garm Spindler.

What drugs are being tested in NCT06562348?

Interventions in NCT06562348: Standard of care, ctDNA-RECIST guided palliative systemic treatment.

What condition does NCT06562348 study?

NCT06562348 studies Gastrointestinal Neoplasm.

Is NCT06562348 still recruiting?

NCT06562348 is currently recruiting now. Last updated 1 May 2025.

Last reviewed 2025-05-01 · How we verify

NCT06562348: ctDNA-RECIST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The ctDNA-RECIST Trial Part One

Recruiting now Phase 2 Last updated 1 May 2025

What this trial tests

Phase 2 trial testing Standard of care in Gastrointestinal Neoplasm in 167 participants. Currently enrolling.

Timeline

15 January 2025

Primary endpoint
1 September 2029

1 September 2030

Quick facts

Lead sponsor	Karen-Lise Garm Spindler
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	167
Start date	15 January 2025
Primary completion	1 September 2029
Estimated completion	1 September 2030
Sites	2 locations across Denmark

Drugs / interventions tested

Standard of care
ctDNA-RECIST guided palliative systemic treatment

Conditions studied

Gastrointestinal Neoplasm — all drugs for Gastrointestinal Neoplasm →

Sponsor

Karen-Lise Garm Spindler — full company profile →

Who can join

18 and older, any sex, with Gastrointestinal Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study investigating if analysis of circulating tumor DNA (ctDNA) can guide palliative treatment in patients with gastrointestinal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST.
Steiniche MM, Lindgaard SC, Chen IM, Johansen JS, et al · · 2025 · cited 3× · PMID 40970773 · DOI 10.1158/1078-0432.ccr-25-0758
Systematic review and meta-analysis of studies assessing circulating tumor DNA kinetics in metastatic colorectal cancer.
Callesen LB, Spindler KG. · · 2026 · PMID 41809060 · DOI 10.1016/j.esmogo.2026.100314

Verify or expand the search:

Other trials of Standard of care

Trials testing the same drug.

NCT06386133 — Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care · NA · not yet recruiting
NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT07274254 — Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease · Phase 3 · not yet recruiting
NCT07284056 — Prevention and Treatment of Early Postoperative Atelectasis Using The MetaNeb System in Patients Underwent Esophagectomy · NA · not yet recruiting
NCT07260344 — Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral · NA · recruiting

Other recruiting trials for Gastrointestinal Neoplasm

Currently open trials in the same condition.

NCT06134687 — Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection · NA · recruiting
NCT06159634 — Traction vs. No Traction in Colonic ESD · NA · recruiting

Other Karen-Lise Garm Spindler trials

Trials by the same sponsor.

NCT04680260 — OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer · Phase 2 · recruiting
NCT05385250 — Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II · NA · active not recruiting
NCT03748680 — IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postop · Phase 2 · unknown
NCT03750175 — OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06562348 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karen-Lise Garm Spindler
Last refreshed: 1 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06562348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing